000			nab a22 7a 4500
999			_c16966 _d16966
003			PC16966
005			20220819132200.0
008			220819b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92953 _aSánchez, Cristina _eInstituto de Investigación imas12
245	0	0	_aEndocannabinoids and Cancer. _h[revisión]
260			_bHandbook of experimental pharmacology, _c2015
300			_a231:449-72.
500			_aFormato Vancouver: Velasco G, Sánchez C, Guzmán M. Endocannabinoids and Cancer. Handb Exp Pharmacol. 2015;231:449-72.
501			_aPMID: 26408171
504			_aContiene 94 referencias
520			_aA large body of evidence shows that cannabinoids, in addition to their well-known palliative effects on some cancer-associated symptoms, can reduce tumour growth in animal models of cancer. They do so by modulating key cell signalling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and cell proliferation in different types of tumours in laboratory animals. By contrast, little is known about the biological role of the endocannabinoid system in cancer physio-pathology, and several studies suggest that it may be over-activated in cancer. In this review, we discuss our current understanding of cannabinoids as antitumour agents, focusing on recent advances in the molecular mechanisms of action, including resistance mechanisms and opportunities for combination therapy approaches.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16966.pdf _ySolicitar documento
942			_2ddc _cREV _n0